-
1تقرير
المؤلفون: Buxton, Lester, Russo, Marc-Thomas, Al-Khalili, Jim, Rocco, Andrea
مصطلحات موضوعية: Quantum Physics
الوصف: We model a quantum system coupled to an environment of damped harmonic oscillators by following the approach of Caldeira-Leggett and adopting the Caldirola-Kanai Lagrangian for the bath oscillators. In deriving the master equation of the quantum system of interest (a particle in a general potential), we show that the potential is modified non-trivially by a new inverted harmonic oscillator term, induced by the damping of the bath oscillators. We analyze numerically the case of a particle in a double-well potential, and find that this modification changes both the rate of decoherence at short times and the well-transfer probability at longer times. We also identify a simple rescaling condition that keeps the potential fixed despite changes in the environmental damping. Here, the increase of environmental damping leads to a slowing of decoherence.
الوصول الحر: http://arxiv.org/abs/2303.09516Test
-
2دورية أكاديمية
المؤلفون: Russo,Marc
مصطلحات موضوعية: Journal of Pain Research
الوصف: Marc Russo Hunter Pain Specialists, Broadmeadow, NSW, AustraliaCorrespondence: Marc Russo, Hunter Pain Specialists, 91 Chatham Street, Broadmeadow, NSW, 2292, Australia, Tel +61 2 4985 1800, Fax +61 2 4940 0322, Email algoguy@gmail.com
وصف الملف: text/html
-
3دورية أكاديمية
المؤلفون: Russo, Marc
المصدر: Journal of Pain Research ; volume Volume 17, page 771-772 ; ISSN 1178-7090
الإتاحة: https://doi.org/10.2147/jpr.s450821Test
https://www.dovepress.com/getfile.php?fileID=97099Test -
4دورية أكاديمية
المؤلفون: Gilligan, Christopher, Volschenk, Willem, Russo, Marc, Green, Matthew, Gilmore, Christopher, Mehta, Vivek, Deckers, Kristiaan, De Smedt, Kris, Latif, Usman, Sayed, Dawood, Georgius, Peter, Gentile, Jonathan, Mitchell, Bruce, Langhorst, Meredith, Huygen, Frank, Baranidharan, Ganesan, Patel, Vikas, Mironer, Eugene, Ross, Edgar, Carayannopoulos, Alexios, Hayek, Salim, Gulve, Ashish, Van Buyten, Jean-Pierre, Tohmeh, Antoine, Fischgrund, Jeffrey, Lad, Shivanand, Ahadian, Farshad, Deer, Timothy, Klemme, William, Rauck, Richard, Rathmell, James, Maislin, Greg, Heemels, Jan Pieter, Eldabe, Sam
المصدر: Neuromodulation: Technology at the Neural Interface ; ISSN 1094-7159
مصطلحات موضوعية: Anesthesiology and Pain Medicine, Neurology (clinical), Neurology, General Medicine
الإتاحة: https://doi.org/10.1016/j.neurom.2024.01.006Test
https://api.elsevier.com/content/article/PII:S1094715924000552?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1094715924000552?httpAccept=text/plainTest -
5دورية أكاديمية
المؤلفون: Brooker, Charles, Russo, Marc, Cousins, Michael, Taylor, Nathan, Holford, Lewis, Martin, Rebecca, Boesel, Tillman, Sullivan, Richard, Hanson, Erin, Gmel, Gerrit, Shariati, Nastaran, Poree, Lawrence, Parker, John
المصدر: Pain Practice. 21(6)
مصطلحات موضوعية: Chronic, closed-loop SCS, evoke, evoked compound action potential, feedback, opioid, pain, spinal cord stimulation, Analgesics, Opioid, Chronic Pain, Humans, Prospective Studies, Quality of Life, Spinal Cord, Spinal Cord Stimulation, Treatment Outcome
الوصف: INTRODUCTION: Chronic pain is a major public health concern, as is the associated use of opioid medications, highlighting the importance of alternative treatments, such as spinal cord stimulation (SCS). Here, we present the final 24-month results of the Avalon study, which investigated the use of the first closed-loop SCS system in patients with chronic pain. The system measures the evoked compound action potentials (ECAPs) elicited by each stimulus pulse and drives a feedback loop to maintain the ECAP amplitude near constant. METHODS: Fifty patients were implanted with the Evoke system (Saluda Medical) and followed over 24-months. Pain, quality of life (QOL), function, sleep, and medication use were collected at baseline and each scheduled visit. ECAP amplitudes and programming adjustments were also monitored. RESULTS: At 24 months, responder rates (≥ 50% pain reduction) and high responder rates (≥ 80% pain reduction) for overall pain were 89.5% and 68.4%, respectively, the latter up from 42.2% at 3 months. Significant improvements from baseline were observed in QOL, function, and sleep over the 24 months, including ≥ 80% experiencing a minimally important difference in QOL and > 50% experiencing a clinically significant improvement in sleep. At 24 months, 82.8% of patients with baseline opioid use eliminated or reduced their opioid intake. Over the course of the study, reprogramming need fell to an average of less than once a year. CONCLUSION: Over a 24-month period, the Evoke closed-loop SCS maintained its therapeutic efficacy despite a marked reduction in opioid use and steady decrease in the need for reprogramming.
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/5nh4x443Test
-
6دورية أكاديمية
المؤلفون: Russo, Marc, Brooker, Charles, Cousins, Michael, Taylor, Nathan, Boesel, Tillman, Sullivan, Richard, Holford, Lewis, Hanson, Erin, Gmel, Gerrit, Shariati, Nastaran, Poree, Lawrence, Parker, John
المصدر: Neurosurgery. 87(4)
مصطلحات موضوعية: Action potentials, Back pain, Chronic pain, Electric stimulation, Feedback, Pain management, Spinal cord stimulation, Adult, Aged, Chronic Pain, Female, Humans, Male, Middle Aged, Pain Management, Pain Measurement, Prospective Studies, Quality of Life, Spinal Cord, Spinal Cord Stimulation, Time Factors, Treatment Outcome
الوصف: BACKGROUND: Spinal cord stimulation (SCS) activates the dorsal column fibers using electrical stimuli. Current SCS systems function in fixed-output mode, delivering the same stimulus regardless of spinal cord (SC) activation. OBJECTIVE: To present long-term outcomes of a novel closed-loop SCS system that aims to maintain the SC activation near a set target level and within a therapeutic window for each patient. SC activation is measured through the evoked compound action potential (ECAP) generated by each stimulus pulse. METHODS: Fifty patients with lower back and/or leg pain who were successfully trialed received a permanent system (Evoke; Saluda Medical, Sydney, Australia). Ratings of pain (visual analog scale), quality of life, function, sleep, and medication use were collected at baseline and at each visit. SC activation levels were reported in summary statistics. The therapeutic window for each individual patient was defined as the range of ECAP amplitudes between sensation threshold and uncomfortably strong stimulation. RESULTS: At 12 mo, the proportion of patients with ≥50% relief was 76.9% (back), 79.3% (leg), and 81.4% (overall), and the proportion with ≥80% pain relief was 56.4% (back), 58.6% (leg), and 53.5% (overall). Patients spent a median of 84.9% of their time with stimulation in their therapeutic window, and 68.8% (22/32) eliminated or reduced their opioid intake. Statistically significant improvements in secondary outcomes were observed. CONCLUSION: The majority of patients experienced more than 80% pain relief with stable SC activation, as measured by ECAP amplitude at 12 mo, providing evidence for the long-term effectiveness of the Evoke closed-loop SCS system.
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/45f8w41hTest
-
7دورية أكاديمية
المؤلفون: Gilligan, Christopher, Volschenk, Willem, Russo, Marc, Green, Matthew, Gilmore, Christopher, Mehta, Vivek, Deckers, Kristiaan, De Smedt, Kris, Latif, Usman, Georgius, Peter, Gentile, Jonathan, Mitchell, Bruce, Langhorst, Meredith, Huygen, Frank, Baranidharan, Ganesan, Patel, Vikas, Mironer, Eugene, Ross, Edgar, Carayannopoulos, Alexios, Hayek, Salim, Gulve, Ashish, Van Buyten, Jean Pierre, Tohmeh, Antoine, Fischgrund, Jeffrey, Lad, Shivanand, Ahadian, Farshad, Deer, Timothy, Klemme, William, Rauck, Richard, Rathmell, James, Maislin, Greg, Heemels, Jan Pieter, Eldabe, Sam
المصدر: Gilligan , C , Volschenk , W , ReActiv8-B investigators , Russo , M , Green , M , Gilmore , C , Mehta , V , Deckers , K , De Smedt , K , Latif , U , Georgius , P , Gentile , J , Mitchell , B , Langhorst , M , Huygen , F , Baranidharan , G , Patel , V , Mironer , E , Ross , E , Carayannopoulos , A , Hayek , S , Gulve , A , Van Buyten , J P , Tohmeh , A , Fischgrund ....
الوصف: Background: Impaired neuromuscular control and degeneration of the multifidus muscle have been linked to the development of refractory chronic low back pain (CLBP). An implantable restorative-neurostimulator system can override the underlying multifidus inhibition by eliciting episodic, isolated contractions. The ReActiv8-B randomized, active-sham-controlled trial provided effectiveness and safety evidence for this system, and all participants received therapeutic stimulation from four months onward. Objective: This study aimed to evaluate the two-year effectiveness of this restorative neurostimulator in patients with disabling CLBP secondary to multifidus muscle dysfunction and no indications for spine surgery. Materials and Methods: Open-label follow-up of 204 participants implanted with a restorative neurostimulation system (ReActiv8, Mainstay Medical, Dublin, Ireland) was performed. Pain intensity (visual analog scale [VAS]), disability (Oswestry disability index [ODI]), quality-of-life (EQ-5D-5L), and opioid intake were assessed at baseline, six months, one year, and two years after activation. Results: At two years (n = 156), the proportion of participants with ≥50% CLBP relief was 71%, and 65% reported CLBP resolution (VAS ≤ 2.5 cm); 61% had a reduction in ODI of ≥20 points, 76% had improvements of ≥50% in VAS and/or ≥20 points in ODI, and 56% had these substantial improvements in both VAS and ODI. A total of 87% of participants had continued device use during the second year for a median of 43% of the maximum duration, and 60% (34 of 57) had voluntarily discontinued (39%) or reduced (21%) opioid intake. Conclusions: At two years, 76% of participants experienced substantial, clinically meaningful improvements in pain, disability, or both. These results provide evidence of long-term effectiveness and durability of restorative neurostimulation in patients with disabling CLBP, secondary to multifidus muscle dysfunction. Clinical Trial Registration: The study is registered on clinicaltrials.gov with ...
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1016/j.neurom.2021.10.011Test
https://pure.eur.nl/en/publications/e819e37f-e353-4095-8aad-cd25d26bbf78Test
https://pure.eur.nl/ws/files/70535892/PIIS1094715921063868.pdfTest
http://www.scopus.com/inward/record.url?scp=85124810046&partnerID=8YFLogxKTest -
8دورية أكاديمية
المؤلفون: Gilligan, Christopher, Volschenk, Willem, Russo, Marc, Green, Matthew, Gilmore, Christopher, Mehta, Vivek, Deckers, Kristiaan, De Smedt, Kris, Latif, Usman, Sayed, Dawood, Georgius, Peter, Gentile, Jonathan, Mitchell, Bruce, Langhorst, Meredith, Huygen, Frank, Baranidharan, Ganesan, Patel, Vikas, Mironer, Eugene, Ross, Edgar, Carayannopoulos, Alexios, Hayek, Salim, Gulve, Ashish, Van Buyten, Jean Pierre, Tohmeh, Antoine, Fischgrund, Jeffrey, Lad, Shivanand, Ahadian, Farshad, Deer, Timothy, Klemme, William, Rauck, Richard, Rathmell, James, Schwab, Frank, Maislin, Greg, Heemels, Jan Pieter, Eldabe, Sam
المصدر: Gilligan , C , Volschenk , W , Russo , M , Green , M , Gilmore , C , Mehta , V , Deckers , K , De Smedt , K , Latif , U , Sayed , D , Georgius , P , Gentile , J , Mitchell , B , Langhorst , M , Huygen , F , Baranidharan , G , Patel , V , Mironer , E , Ross , E , Carayannopoulos , A , Hayek , S , Gulve , A , Van Buyten , J P , Tohmeh , A , ....
الوصف: Background: Restorative neurostimulation is a rehabilitative treatment for patients with refractory chronic low back pain (CLBP) associated with dysfunction of the lumbar multifidus muscle resulting in impaired neuromuscular control. The ReActiv8-B randomized, sham-controlled trial provided evidence of the effectiveness and safety of an implanted, restorative neurostimulator. The two-year analysis previously published in this journal demonstrated accrual of clinical benefits and long-term durability. Objective: Evaluation of three-year effectiveness and safety in patients with refractory, disabling CLBP secondary to multifidus muscle dysfunction and no indications for spine surgery. Materials and Methods: Prospective, observational follow-up of the 204 implanted trial participants. Low back pain visual analog scale (VAS), Oswestry Disability Index (ODI), EuroQol quality of life survey, and opioid intake were assessed at baseline, six months, and one, two, and three years after activation. The mixed-effects model repeated measures approach was used to provide implicit imputations of missing data for continuous outcomes and multiple imputation for proportion estimates. Results: Data were collected from 133 participants, and 16 patients missed their three-year follow-up because of coronavirus disease restrictions but remain available for future follow-up. A total of 62% of participants had a ≥ 70% VAS reduction, and 67% reported CLBP resolution (VAS ≤ 2.5cm); 63% had a reduction in ODI of ≥ 20 points; 83% had improvements of ≥ 50% in VAS and/or ≥ 20 points in ODI, and 56% had these substantial improvements in both VAS and ODI. A total of 71% (36/51) participants on opioids at baseline had voluntarily discontinued (49%) or reduced (22%) opioid intake. The attenuation of effectiveness in the imputed (N = 204) analyses was relatively small and did not affect the statistical significance and clinical relevance of these results. The safety profile remains favorable, and no lead migrations have been observed to date. ...
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1016/j.neurom.2022.08.457Test
https://pure.eur.nl/en/publications/c72c09da-d796-4e5e-9437-79a4f67c468bTest
https://pure.eur.nl/ws/files/70535672/PIIS1094715922012545.pdfTest
http://www.scopus.com/inward/record.url?scp=85139052661&partnerID=8YFLogxKTest -
9دورية أكاديمية
المؤلفون: Russo, Marc, Graham, Brett, Santarelli, Danielle M.
المساهمون: The University of Newcastle. College of Health, Medicine & Wellbeing, School of Medicine and Public Health
مصطلحات موضوعية: analgesia, gabapentin, glial cells, neuropathic pain, pharmacologic actions
الوصف: Background: Gabapentin is a recommended first-line agent for treating neuropathic pain; however, its efficacy rate is reportedly low, and the risk of adverse events is high. A plausible explanation for this lies with its wide range of actions, the entirety of which have yet to be fully elucidated. Methods: A review of the literature was conducted on gabapentin's known and proposed analgesic mechanisms of action, as well as potentially opposing or detrimental actions. Results: Gabapentin's classical analgesic mechanisms involve direct attenuation of excitatory neurotransmission in the spinal cord via inhibition of neuronal ion channels, while indirect mechanisms include descending inhibition and block of injury-evoked synaptogenesis. Glial effects have also been reported; however, whether they are neuroprotective or detrimental is unknown. Furthermore, data from animal models do not reflect clinical outcomes. Conclusions: Gabapentin's clinical use should be reconsidered according to the net effects of its numerous assumed actions, including the tripartite synapse and oligodendrocyte effects. Whether it is doing more harm than good, especially in the scenarios of incomplete or loss of response, warrants consideration when prescribing gabapentin.
العلاقة: Pain Practice Vol. 23, Issue 1, p. 63-69; http://hdl.handle.net/1959.13/1480474Test; uon:50511
-
10دورية أكاديمية
المؤلفون: Taylor, Rod S., Soliday, Nicole, Leitner, Angela, Hunter, Corey W., Staats, Peter S., Li, Sean, Thomson, Simon, Kallewaard, Jan W., Russo, Marc, Duarte, Rui V.
الوصف: Objectives: Pain score, functional disability, and health-related quality of life (HRQoL) are core outcome domains for chronic pain clinical trials. Although greater levels of pain reduction have been shown to be linked to larger gains in HRQoL, little is known of the association between HRQoL and disability in the setting of chronic pain. The aims of this study were to 1) investigate the association between functional disability and HRQoL and 2) estimate the utility values associated with levels of functional disability in patients treated with evoked compound action potential (ECAP) spinal cord stimulation (SCS) for chronic pain. Materials and Methods: Data on functional disability assessed using the Oswestry Disability Index (ODI) and HRQoL (EQ-5D-5L) were collected from 204 patients with an Evoke ECAP-SCS device and followed up to 12 months. SF-6D utility scores also were retrieved for 134 of these patients. Multivariable linear regression models adjusted for baseline utility values and patient demographics were used to compare differences in utility values across ODI categories. Results: Significant improvements in functional disability and HRQoL were observed at three- and 12-month follow-up after SCS. Patients reporting “minimum disability,” “moderate disability,” “severe disability,” and “crippled” had mean EQ-5D scores of 0.82, 0.73, 0.59, and 0.45, respectively. The mean change in EQ-5D score was 0.007 per unit change in total ODI score. The R2 statistic showed a moderate level association (49%–64% of variance in EQ-5D explained by ODI). Conclusion: ECAP-SCS results in significant improvements in functional disability and HRQoL. This study shows that improvement in function of people with chronic pain before and after ECAP-SCS is associated with improvement in HRQoL.
وصف الملف: text
العلاقة: https://eprints.gla.ac.uk/273288/2/273288.pdfTest; Taylor, R. S. , Soliday, N., Leitner, A., Hunter, C. W., Staats, P. S., Li, S., Thomson, S., Kallewaard, J. W., Russo, M. and Duarte, R. V. (2023) Association between levels of functional disability and health-related quality of life with spinal cord stimulation for chronic pain. Neuromodulation , 26(5), pp. 1039-1046. (doi:10.1016/j.neurom.2022.04.039 ) (PMID:35643846)
